 |
 |
|
|
RESÚMENES SEPTIEMBRE 2004 |
Psychotic Disorders & Antipsychotics
(Requiere estar conectado a internet. Haga un click en la
información del journal)
Catherine Curran, Neetha Byrappa, Andrew Mcbride
The British Journal of Psychiatry (2004) 185: 196-204
Mendrek, K. R.
Laurens, K. A. Kiehl, E. T. C. Ngan,
E. Stip, and P. F. Liddle
The British Journal of Psychiatry (2004) 185: 205-214
Annamari Tuulio-Henriksson, Timo Partonen, Jaana Suvisaari, Jari Haukka, and Jouko Lönnqvist
The British Journal of Psychiatry (2004) 185: 215-219
Psychosis, victimisation and childhood disadvantage. Evidence from the second British National Survey of Psychiatric Morbidity
Paul E. Bebbington, Dinesh Bhugra, Traolach Brugha, Nicola
Singleton, Michael Farrell, Rachel Jenkins, Glyn
Lewis, Howard Meltzer
The British Journal of Psychiatry (2004) 185: 220-226
Middle and Inferior Temporal Gyrus Gray Matter Volume Abnormalities in Chronic Schizophrenia: An MRI Study
Toshiaki Onitsuka, Martha E. Shenton, Dean F. Salisbury, Chandlee
C. Dickey, Kiyoto Kasai, Sarah K. Toner, Melissa Frumin,
Ron Kikinis, Ferenc A. Jolesz, and Robert W. McCarley
Am J Psychiatry 161:1603-1611,
September 2004
Equivalent
Occupancy of Dopamine D1 and D2 Receptors With Clozapine: Differentiation
From Other Atypical Antipsychotics
Johannes Tauscher, Tabasum Hussain, Ofer Agid,
N. Paul L.G. Verhoeff, Alan A. Wilson, Sylvain Houle, Gary Remington, Robert B. Zipursky,
and Shitij Kapur
Am J Psychiatry 161:1620-1625,
September 2004
Cognitive Enhancement Therapy for
Schizophrenia. Effects of a
2-Year Randomized Trial on Cognition and Behavior
Gerard
E. Hogarty; Samuel Flesher; Richard Ulrich, Mary
Carter, Deborah Greenwald, Michael Pogue-Geile, Matcheri Kechavan, Susan Cooley,
Ann Louise DiBarry, Ann Garrett, Haranath
Parepally, Rebecca Zoretich
Arch Gen Psychiatry. 2004;61:866-876.
A
cross-validation study on the relationship between central D2
receptor occupancy and serum perphenazine
concentration
Mirjam Talvik,
Anna-Lena Nordström, Niels-Erik Larsen,
Aurelija Jucaite,
Simon 
ervenka, Christer Halldin and Lars Farde
Psychopharmacology 2004; Volume 175, Number
2: 148 - 153
Suicidality and second generation anytipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period
Y Barak, I Mirecki, HY Knobler, Z Natan and D Aizenberg
Psychopharmacology 2004; Volume 175, Number
2: 215 - 219
Intramuscular Haloperidol or Lorazepam and QT Intervals in Schizophrenia.
Harvey AT, Flockhart D, Gorski JC, Greenblatt DJ, Burke M, Werder S,
Preskorn SH.
J Clin Pharmacol.
2004 Oct;44(10):1173-84.
Perinatal
inflammatory cytokine challenge results in distinct neurobehavioral alterations
in rats: implication in psychiatric disorders of developmental origin
Manavu Tohmi,
Noriko Tsuda, Yuichiro
Watanabe, Akiyoshi Kakita
and Hiroyuki Nawa Neuroscience
Research Volume 50, Issue 1, September 2004, Pages 67-75
Delinquency
and criminal offenses in former schizophrenic inpatients 7–12 years following
discharge
Michael Soyka, Veronika Morhart-Klute and Heinz Schoech
European Archives of Psychiatry and Clinical
Neuroscience 2004; Volume 254, Number 5: 289 - 294
Predictors
of response in a sample of treatment-resistant psychotic patients on clozapine
Antonio Ciapparelli, Francesca Ducci, Claudia Carmassi,
Marina Carlini, Rosemma Paggini, Mario Catena, Matteo Bottai and Liliana Dell
Osso
European Archives of Psychiatry and Clinical
Neuroscience 2004;Volume 254, Number 5: 343 - 346
The Atypical Antipsychotic Therapy and Metabolic
Issues National Survey: Practice Patterns and Knowledge of Psychiatrists.
Newcomer, John W.; Nasrallah,
Henry A.; Loebel,
Journal of Clinical Psychopharmacology.
24 Supplement 1:S1-S6, October 2004.
Mari Murashita, Ichiro Kusumi, Takeshi
Inoue, Yoshito Takahashi, Hiroshi Hosoda,
Kenji Kangawa and Tsukasa Koyama
N-methyl-
-aspartate antagonists as drug models of schizophrenia: a
surprising link to tobacco smoking
Edward
F. Domino, Diana Mirzoyan and Hideo Tsukada
Roland Rosmond
Relationship between antipsychotic
medication treatment and new cases of diabetes among psychiatric inpatients.
Citrome L, Jaffe A, Levine J, Allingham B, Robinson J.
Psychiatr Serv. 2004 Sep;55(9):1006-13
Nuria Durany
and Johannes Thome
P. Fossion, L. Servais, M. -C. Rejas, Y. Ledoux,
Abnormalities
in the dopamine system in schizophrenia may lie in altered levels of dopamine
receptor-interacting proteins
Jie Bai,
Fang He, Svetlana I. Novikova, Ashiwel
S. Undie, Stella Dracheva, Vahram Haroutunian and Michael S.
Lidow
Placebo-controlled
trial of lamotrigine added to conventional and
atypical antipsychotics in schizophrenia
Ilana Kremer, Agnes Vass, Ielena Gorelik, Gali Bar, Monica Blanaru, Daniel
C. Javitt and Uriel Heresco-Levy
A
controlled study of brain structure in monozygotic twins concordant and
discordant for schizophrenia
Neeltje E.M. van Haren,
Marco M. Picchioni, Colm
McDonald, Nicolette Marshall, Nadia Davis, Tracey Ribchester, Hilleke E. Hulshoff Pol, Tonmoy
Sharma, Pak Sham, René S. Kahn and Robin Murray
Can J Psychiatry 2004:49;564–569
Differential
effects of typical and atypical antipsychotics on
nerve growth factor and choline acetyltransferase
expression in the cortex and nucleus basalis of rats
Vinay Parikh, Mohammad M. Khan, Alvin
Terry and Sahebarao P. Mahadik
Reduced plastic brain responses in schizophrenia: a
transcranial magnetic stimulation study
Paul B.
Fitzgerald, Timothy L. Brown, Natasha A. U. Marston,
Tom Oxley, Anthony de Castella, Z. Jeff Daskalakis and J. Kulkarni
Peter A.
Gochman, Deanna Greenstein, Alexandra Sporn, Nitin Gogtay,
Rob Nicolson, Audrey Keller, Marge Lenane, Francis Brookner and
Judith L. Rapoport
Yoram Barak,
Chaim Y. Knobler and Dov Aizenberg
Matcheri Keshavan,
Mujeeb Shad, Paul Soloff
and Nina Schooler
Jacinta
B. Williams, Pierre J. Mallorga, P. Jeffrey Conn, Douglas J. Pettibone and Cyrille Sur
Impact
of atypical antipsychotics on quality of life,
self-report of symptom severity, and demand of services in chronically
psychotic patients
Peter L.
Zhang, Juan M. Santos, John Newcomer, Barbara A. Pelfrey,
Mark C. Johnson and Gabriel A. de Erausquin
Jose R. Carrión-Baralt, Zulma Fuentes-Rivera, James Schmeidler
and Jeremy M. Silverman
Compliance in Schizophrenia:Psychopathology, Side Effects, and Patients'
Attitudes Toward the Illness and Medication
Maria A.
Rettenbacher, Alex Hofer, Ursula Eder,
Martina Hummer, Georg Kemmler,
Elisabeth M. Weiss, and Wolfgang W. Fleischhacker
J Clin Psychiatry 2004;65:1211-1218
Olanzapine
treatment for tardive dyskinesia
in schizophrenia patients: a prospective clinical trial with patients
randomized to blinded dose reduction periods
Bruce J.
Kinon, Dilip V. Jeste, Sara Kollack-Walker,
Virginia Stauffer and Hong Liu-Seifert
Differential
expression of mitogen-activated protein kinases and immediate early genes fos and jun in thalamus in
schizophrenia
Svetlana
V. Kyosseva
The atypical antipsychotic drug clozapine
enhances chronic PCP-induced regulation of prefrontal cortex 5-HT2A
receptors
Lucinda
J. Steward, Matthew D. Kennedy, Brian J. Morris and Judith A. Pratt
Application of an empiric Bayesian data mining
algorithm to reports of pancreatitis associated with
atypical antipsychotics.
Hauben M.
Pharmacotherapy 2004;24(9):1122-1129.
Role of neuroactive
steroid allopregnanolone in antipsychotic-like action
of olanzapine in rodents.
Ugale RR, Hirani K, Morelli M,
Neuropsychopharmacology 2004;29(9):1597-1609.
Perospirone hydrochloride: The novel atypical antipsychotic agent with high affinities
for 5-HT2, D2 and 5-HT1A receptors.
Ishibashi T, Ohno Y.
Biogenic Amines 2004;18(3-6):307-317.
Selective
serotonin re-uptake inhibitor augmentation in the treatment of negative
symptoms of schizophrenia
Henry
Silver
Expert Opinion on Pharmacotherapy. 2004, vol. 5, no. 10, pp. 2053 - 2058
Amisulpride
augmentation of clozapine: an open non-randomized
study in patients with schizophrenia partially responsive to clozapine.
Munro J, Matthiasson P, Osborne S, Travis M, Purcell S, Cobb AM, Launer M, Beer MD, Kerwin R
Acta Psychiatr Scand. 2004 Oct;110(4):292-8
Acute amygdalar activation induces an upregulation
of multiple monoamine G protein coupled pathways in rat hippocampus
F
M Benes, R E Burke, J Walsh, S Berretta, D Matzilevich, M Minns and C Konradi